CPP
ICPT

Crow Point Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Crow Point Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,800
Closed -$64K – 133
2019
Q1 		$64K Buy
+3,800
New +$415K 0.01% 117

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Crow Point Partners's ICPT Position: Q4 2019 in Review

Crow Point Partners opened a new position in Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2019: 1,800 shares worth $222K. The stake represents 0.35% of the portfolio and ranks #60 among its holdings. This is a return to the name: Crow Point Partners previously reported a position in ICPT as recently as Q1 2019.

Crow Point Partners first reported a position in ICPT in Q1 2019 and has held it in 2 quarters since. The position peaked at $256K in Q1 2019. 215 funds tracked by Wall St. Rank hold ICPT as of Q4 2019.

  • Crow Point Partners held 1,800 shares of Intercept Pharmaceuticals, Inc. worth $222K as of Q4 2019.
  • Intercept Pharmaceuticals, Inc. was a new Crow Point Partners position in Q4 2019.
  • Intercept Pharmaceuticals, Inc. made up 0.35% of Crow Point Partners's portfolio in Q4 2019, its #60 holding.
  • Crow Point Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2019 and has held it in 2 quarters since.
  • Crow Point Partners's Intercept Pharmaceuticals, Inc. position peaked at $256K in Q1 2019.
  • 215 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.